Gastrointestinal disorder
3 papers
- Human trial1
- Humans2
Latest
10 in 12 monthsFrontiers in Pharmacology
Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database
Cohort study of 42,941 peoplePopulations
The Lancet Diabetes & Endocrinology
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial
Randomised trial in 179 peopleOverweight
The Lancet Diabetes & Endocrinology
Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
Randomised trial in 485 peopleType 2 diabetes
The Lancet Diabetes & Endocrinology
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial
Randomised trial in 242 peopleSemaglutide
Clinics and Research in Hepatology and Gastroenterology
Safety and effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors in liver transplant recipients with diabetes
Cohort study of 41 peopleSGLT2 inhibitors
ADA Scientific Sessions 2026 Abstract
UBT251, a Triple Hormone Receptor Agonist in Adults with Overweight or Obesity: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Trial
Trial in peopleInterventions
ADA Scientific Sessions 2026 Abstract
Efficacy and Safety of cAMP-Biased Ecnoglutide vs. Unbiased Semaglutide in Adults with Obesity: Twenty-Week Results from a Multicenter, Randomized, Open-Label, Phase 2 Study
Trial in peopleInterventions